NCT04845841View on ClinicalTrials.gov

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Interventions
DRUG

Elinzanetant (BAY3427080) treatment A

Single oral dose

DRUG

Elinzanetant (BAY3427080) treatment B

Single oral dose

Trial Locations (1)

68167

CRS Clinical-Research-Services Mannheim GmbH, Mannheim

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04845841 - Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body | Biotech Hunter | Biotech Hunter